Mississauga, ON -- (SBWire) -- 06/11/2013 --AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “Advaxis Aims for Orphan Drug Status in Cervical and Head and Neck Cancers.”
Companies mentioned in this article include Advaxis, Inc. (OTCBB:ADXS) and Sanofi (NYSE:SNY).
Article Excerpt:
The U.S. Food and Drug Administration has several special designations for expediting development or protecting drugs that meet areas of great unmet medical need. The Orphan Drug Act provides for a special designation for therapeutic candidates treating rare diseases or conditions typically affecting fewer than 200,000 people in the United States. Designation of Orphan Drug status provides a company with several benefits, such as clinical protocol assistance from the FDA, seven-year marketing exclusivity, tax credits, marketing applications that are free of a prescription drug user fee and more.
Some may initially think that the small populations of patients in the rare disorder category may limit revenue potential, but these therapeutics can command high margins. Biotechnology legend Henri Termeer helped build Genzyme into a pharma giant through biologics (that are not easily copied by generics) targeting rare genetic disorders. Genzyme was eventually bought by Sanofi (NYSE:SNY) for $20.1 billion in 2011.
Upstart biotech Advaxis, Inc. (OTCBB:ADXS) is certainly not a comparable to a behemoth like Genzyme, but the clinical stage company is beating down the path of Orphan Drug designations with their immunotherapy therapeutics that seems worth an investigation. Advaxis is in the midst of six clinical trials, including three Phase II trials for cervical cancer and Cervical Intraepithelial Neoplasia, or CIN. All tallied, the company has 15 immunotherapies in development for cancers and infectious diseases.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/363/advaxis-aims-for-orphan-drug-status-in-cervical-and-head-and-neck-cancers.htm
About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.
All Penny Stocks.com News: Advaxis Aims for Orphan Drug Status in Cervical and Head and Neck Cancers